MEDLINE INC (MDLN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$36.590.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Broken: Primary pillar broken — Maintain Adjusted EBITDA outlook of $3.5 to $3.6 billion: EBITDA margin 9.2% vs target $3.5B.
Medline aims for adjusted EBITDA near $3.55 billion in 2026. It targets organic sales growth of 8% to 9%. The company announced a share buyback program, showing capital return focus. Recent earnings beats support solid execution.
Medline faces supply chain risks after a warehouse fire. FDA warnings highlight quality control problems. These issues could hurt sales and margins.
The price is about 53% above our fair value near $28 but 37% below the Street median near $45. The market expects moderate growth, but we see risks from operational challenges.
Breaks if: Adjusted EBITDA falls below $3.5 billion in FY26
Breaks if: organic sales growth falls below 7% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
MDLN represents a durable compounder with a focus on organic sales growth and adjusted EBITDA. The current thesis state is stable, supported by strong recent financial performance and a favorable sector backdrop.
The market seems to have priced in a justified valuation, with low expectations for fragility. MDLN's valuation is slightly above its peers, indicating that investors expect steady performance but are cautious about potential risks.
Fundamentals are likely to show continued strength, as MDLN has reported organic sales growth ahead of initial guidance. However, the mixed status of management priorities, particularly regarding adjusted EBITDA, suggests some challenges may lie ahead.
The long-term thesis hinges on management's ability to maintain guidance and execute on their priorities. Key factors include the performance of sector bellwethers and the overall health of the job market, which could impact MDLN's growth.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Achieve organic sales growth in the range of 8% to 9% for the full year 2026.
Breaks if: additional FDA warnings or prolonged supply shortages
Breaks if: no buyback program announced or executed within 1 year
Implement a share repurchase program as part of capital allocation strategy.
In the next 1 to 3 years, MDLN's performance will depend on its execution against set targets and external economic conditions. Not investment advice.